Patrys secures ethics approval for Phase 1A clinical trial on delirium candidate
Patrys has received HREC approval to commence its Phase 1A clinical trial of RLS-2202 for the treatment of delirium in acute care settings.
Market Cap $83.27B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.